A report from Dr. Jörg Oliver Thumfart*, Labormedizinisches Zentrum Dr. Risch “We successfully introduced the automated, turbidimetric assay for fecal calprotectin, the BÜHLMANN fCAL® turbo, on our Roche cobas® c501
A Report of Martina Kobelt* and Karin Jung**, Zentrum für Labormedizin, KS St. Gallen, Switzerland *Senior Laboratory Technician Core Lab, **Deputy Head of Department Core Lab/FAMH Candidate Clinical Chemistry, Centre
Unilabs Portugal, a private European lab chain, made a comprehensive evaluation of different Calprotectin assays on the market. Finally, they choose the BÜHLMANN fCAL® turbo simply because it is faster,
Follow the Evolution of Calprotectin Testing at James Cook University Hospital This interview with Mr Andrew Teggert, Clinical Scientist, James Cook University Hospital, Middlesbrough, discusses recent changes made to the faecal calprotectin testing
Mary O’Connell née Deasy, Biochemistry Department, Mercy University Hospital, Cork In issue 2017-3 of Leading Edge, Mary O’Connell detailed her evaluation of the BÜHLMANN fCAL® turbo assay on the Abbott Architect C8000 analyser in comparison
Mary O’Connell née Deasy, Biochemistry Department, Mercy University Hospital, Cork, Ireland The Mercy University hospital is one of the largest users of the IBDoc test, with almost 500 patients using the system to
Mary O’Connell née Deasy, Biochemistry Department Mercy University Hospital Cork, Ireland describes her experience introducing the BÜHLMANN fCAL turbo assay onto her department’s Abbott Architect C8000. At the Biochemistry Department
Faecal Calprotectin is a new biomarker which is helping to save money for the NHS by preventing unnecessary procedures on patients by screening out patients with IBS who do not require endoscopies.
The symptoms of functional disorders such as Irritable Bowel Syndrome (IBS) and organic inflammatory intestinal disease (IBD) can be very similar in presentation but are two very different medical conditions.